Compass Therapeutics, Inc. (CMPX) stock
CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.01 (-0.93%)
Close on Nov 11, 2026Market cap $149.51MP/E –Yield –
Compass Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Compass Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$93.99M. For fiscal 2025 it was -$72.56M. The highest annual figure on record is -$25.41M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$72.56M | – |
| FY2024 | Dec 31, 2024 | -$56.04M | – |
| FY2023 | Dec 31, 2023 | -$49.66M | – |
| FY2022 | Dec 31, 2022 | -$40.87M | – |
| FY2021 | Dec 31, 2021 | -$81.32M | – |
| FY2020 | Dec 31, 2020 | -$25.41M | – |
| FY2019 | Dec 31, 2019 | -$31.95M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$28.77M | – |
| Q2 FY2026 | Jun 30, 2026 | -$26.96M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.97M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.83M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.33M | – |
| Q2 FY2019 | Sep 30, 2019 | -$7.88M | – |
| Q1 FY2019 | Jun 30, 2019 | -$18.17M | – |
See a number that looks wrong?